Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%

Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor.

Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday.

Lipfendra blocks the action of PCSK9, a naturally occurring protein that affects how the liver removes LDL ("bad") cholesterol from the bloodstream.

"PCSK-9 is a protein that works in the liver, preventing the recycling of LDL receptors, as a result increasing bad cholesterol in the blood," Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital.

Read Full Article Here